News und Analysen
DGAP-Adhoc: Newron gibt Geschäftsergebnisse 2019 und Ausblick 2020 bekannt
DGAP-Adhoc: Newron gibt Geschäftsergebnisse 2019 und Ausblick 2020 bekannt
DGAP-News: Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia
DGAP-News: Newron Expands Global Rett Syndrome Burden of Illness Survey Outreach to Europe and Australia
DGAP-News: Newron weitet internationale Studie zur Untersuchung der Krankheitslast von Rett-Syndrom auf Europa und Australien aus
DGAP-News: Newron weitet internationale Studie zur Untersuchung der Krankheitslast von Rett-Syndrom auf Europa und Australien aus
DGAP-Adhoc: Newron gibt Beginn einer neuen klinischen Studie mit Evenamide in Schizophrenie-Patienten bekannt, nach Genehmigung des Studienplans durch FDA
DGAP-Adhoc: Newron gibt Beginn einer neuen klinischen Studie mit Evenamide in Schizophrenie-Patienten bekannt, nach Genehmigung des Studienplans durch FDA
DGAP-News: Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA
DGAP-News: Newron announces initiation of new clinical trial with Evenamide in patients with schizophrenia, following approval of plan by FDA
DGAP-News: Newron gibt Beginn einer neuen klinischen Studie mit Evenamide in Schizophrenie-Patienten bekannt, nach Genehmigung des Studienplans durch FDA
DGAP-News: Newron gibt Beginn einer neuen klinischen Studie mit Evenamide in Schizophrenie-Patienten bekannt, nach Genehmigung des Studienplans durch FDA
DGAP-Adhoc: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data
DGAP-Adhoc: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data
DGAP-News: Newron Pharmaceuticals beantragt bei US-Zulassungsbehörde FDA ein Type A Meeting vor Entblindung der Daten der STARS-Studie
DGAP-News: Newron Pharmaceuticals beantragt bei US-Zulassungsbehörde FDA ein Type A Meeting vor Entblindung der Daten der STARS-Studie
DGAP-News: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data
DGAP-News: Newron Pharmaceuticals to Request Type A FDA Meeting Prior to Unblinding of STARS Clinical Trial Data
DGAP-News: Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
DGAP-News: Newron Receives Second Tranche from Financing Agreement with European Investment Bank (EIB)
DGAP-News: Newron erhält zweite Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
DGAP-News: Newron erhält zweite Tranche aus der Finanzierungsvereinbarung mit der Europäischen Investitionsbank (EIB)
DGAP-News: Newron erhält von der FDA den Rare-Pediatric-Disease-Status für Sarizotan zur Behandlung des Rett-Syndroms
DGAP-News: Newron erhält von der FDA den Rare-Pediatric-Disease-Status für Sarizotan zur Behandlung des Rett-Syndroms
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
DGAP-News: Newron Receives FDA Rare Pediatric Disease Designation for Sarizotan for the Treatment of Rett Syndrome
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
EQS-News: Newron announces positive top-line results from potentially pivotal Phase II/III study 008A with evenamide in schizophrenia patients
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Data from Newron’s study 014/015 and an evenamide clinical development outlook presented at the 2024 Annual Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
EQS-News: Newron presents 2023 financial results and provides 2024 outlook
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EQS-News: Newron announces agreement with the European Investment Bank (EIB) to extend the near-term tranche repayment dates of its 2018 financing agreement
EQS-News: Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
EQS-News: Newron enters into an agreement for the subscription of up to 2.05 million newly issued shares; Proceeds of up to EUR 15.0 million
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
EQS-News: Newron reports exceptional one-year results of study 014/15 with evenamide in treatment-resistant schizophrenia (TRS)
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
EQS-News: Newron completes enrollment of schizophrenia patients in potentially pivotal study 008A with Evenamide
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
EQS-News: Newron TRS study 6 months’ results: Evenamide substantially improves patients to an extent that they no longer meet protocol entry criteria
EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
EQS-News: Newron to present three posters on its clinical program evaluating evenamide in the treatment of schizophrenia at the 36th European College of Neuropsychopharmacology Congress
EQS-News: Newron appoints Margarita Chavez as board advisor
EQS-News: Newron appoints Margarita Chavez as board advisor
EQS-News: Newron announces H1 2023 results and provides R&D update
EQS-News: Newron announces H1 2023 results and provides R&D update
EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)
EQS-News: Newron presents exciting new data from study 014/015 at CINP World Congress of Neuropsychopharmacology and the 2023 Congress of the Schizophrenia International Research Society (SIRS)